Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Asian Stocks Slide as AI Spending Fears and Global Central Bank Decisions Weigh on Markets 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
Lab-grown meat: you may find it icky, but it could drive forward medical research 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
